Page last updated: 2024-11-12

a 74273

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 74273: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID20832757
MeSH IDM0209805

Synonyms (5)

Synonym
a 74273
130316-95-9
a-74273
6-cyclohexyl-4-hydroxy-5-[2-[1-[4-(methoxymethoxy)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]oxyhexanoylamino]-n-(3-morpholin-4-ylpropyl)-2-propan-2-ylhexanamide
AKOS040747668

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The development of orally active renin inhibitors has been plagued by limited bioavailability in animals and humans."( Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
Baker, WR; Barlow, J; Boyd, S; Cohen, J; Fung, AK; Kleinert, HD; Kovar, P; Polakowski, JS; Stein, HH; Verburg, KM, 1992
)
0.28
" A-74273 represents a new class of potent and orally bioavailable nonpeptidic renin inhibitors."( Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.
Baker, WR; Barlow, JL; Boyd, SA; Fung, AK; Klinghofer, V; Kovar, PJ; Mantei, RA; Polakowski, JS; Stein, HH; Verburg, KM, 1993
)
0.29
" Our prior efforts led to the identification of A-74273 [1,R = 3-(4-morpholino)propyl], with a bioavailability of 26 +/- 10% [10 mg/kg intraduodenally (id), dog]."( Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.
Baker, WR; Barlow, JL; Boyd, SA; Cohen, J; Fung, AK; Klinghofer, V; Mantei, RA; Stein, HH; Verburg, KM; Wessale, JL, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" This favorable pattern also was observed after oral dosing in conscious animals, except in monkeys."( Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
Baker, WR; Barlow, J; Boyd, S; Cohen, J; Fung, AK; Kleinert, HD; Kovar, P; Polakowski, JS; Stein, HH; Verburg, KM, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]